LusaACarlsonA. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: A case series. Lupus2018; Epub ahead of print, DOI: 10.1177/0961203318770023.
2.
MarounMCOsoskiRAndersenJCDharJP. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus. Lupus2015; 24: 746–750.
3.
MagnanoLEnriquezHEsteveJCerveraREspinosaG. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus. The Journal of Rheumatology2014; 41: 1895–1896.
4.
AlkaabiJKAlkindiSRiyamiNAZiaFBallaLMBallaSM. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus2012; 21: 1571–1574.
5.
Catala-LopezFCorralesIde la Fuente-HonrubiaCet al.Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Medicina Clinica2015; 145: 511–519.
6.
HisadaRKatoMSugawaraEet al.Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: A longitudinal study. Journal of Thrombosis and Haemostasis2017; 15: 1782–1787.
7.
MoulisGAudemard-VergerAArnaudLet al.Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. Autoimmunity Reviews2016; 15: 203–209.
8.
KandaMKondoMYamamotoSMukaiM. [Case report: A thromboembolic event in a patient with antiphospholipid antibody-associated thrombocytopenia during eltrombopag therapy.]. Nihon Naika Gakkai zasshi [The Journal of the Japanese Society of Internal Medicine]2013; 102: 1461–1463.
9.
BoulonCVircoulonMConstansJ. Eltrombopag in systemic lupus erythematosus with antiphospholipid syndrome: Thrombotic events. Lupus2016; 25: 331–331.
10.
LaMoreauxBBarbar-SmileyFArdoinSMadhounH. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist. Seminars in Arthritis and Rheumatism2016; 45: e10–e12.